Cas:190082-01-0 5-chloro-1-[4-(trifluoromethoxy)phenyl]tetrazole manufacturer & supplier

Chemical Name:5-chloro-1-[4-(trifluoromethoxy)phenyl]tetrazole

CAS.NO:190082-01-0

Synonyms:5-chloro-1-(4-trifluoromethoxyphenyl)-1h-tetrazole

Molecular Formula:C₈H₄ClF₃N₄O

Molecular Weight:264.59200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:52.83000

Exact Mass:264.00300

LogP:2.21430

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-chloro-1-(4-trifluoromethoxyphenyl)-1h-tetrazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-chloro-1-(4-trifluoromethoxyphenyl)-1h-tetrazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-chloro-1-(4-trifluoromethoxyphenyl)-1h-tetrazole Use and application,5-chloro-1-(4-trifluoromethoxyphenyl)-1h-tetrazole technical grade,usp/ep/jp grade.

Related News: The rest of South Korea will also consider stopping issuing tourist visas to Chinese nationals, said Park Neung-hoo, the government��s minister of health and welfare. All travelers from China will be separated from the other arrivals for heightened screening at airports. 5-chloro-1-[4-(trifluoromethoxy)phenyl]tetrazole manufacturer ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety. 5-chloro-1-[4-(trifluoromethoxy)phenyl]tetrazole supplier The rest of South Korea will also consider stopping issuing tourist visas to Chinese nationals, said Park Neung-hoo, the government��s minister of health and welfare. All travelers from China will be separated from the other arrivals for heightened screening at airports. 5-chloro-1-[4-(trifluoromethoxy)phenyl]tetrazole vendor As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 5-chloro-1-[4-(trifluoromethoxy)phenyl]tetrazole factory AXON is planning a follow-up trial that will include a better-defined group of Alzheimer’s patients suffering from both amyloid plaques and tau tangles, Novak said.